⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JBIO News
Jade Biosciences, Inc. Common Stock
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
globenewswire.com
JBIO
Jade Biosciences to Participate in Upcoming Conferences
globenewswire.com
JBIO
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
globenewswire.com
JBIO
Jade Biosciences Announces $135 Million Private Placement
globenewswire.com
JBIO
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
globenewswire.com
JBIO